INTERPACE BIOSCIENCES, INC. (IDXG) Form 8-K — Oct 15, 2026

$IDXGForm 8-KItems 2.02, 9.01Filed Oct 15, 2026, 6:10 AM ET0001493152-26-047090Original filing

Interpace Biosciences announced preliminary unaudited Q3 2026 revenue of $10.1 million to $10.4 million, up approximately 11% to 14% from Q2 2026 revenue of $9.1 million and up 15% to 18% from Q3 2025 revenue of $8.8 million. The results were disclosed via 8-K Item 2.02 alongside a free writing prospectus referencing a filed Form S-1 registration statement, suggesting an offering may be underway or pending.

Key figures

Revenue: $10.1 million to $10.4 million (preliminary Q3 2026)
Revenue Yoy: approximately 15% to 18%
Qoq growth: approximately 11% to 14%
Q2 2026 revenue: $9.1 million
Q3 2025 revenue: $8.8 million

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.